Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Technical Presentation (July 2021)

46 slides from Cellectis's technical presentation, July 2021

  1. Slide 1: Commitment to a Cure: Cellectis Innovation Days Episode 4

    COMMITMENT TO A CURE Cellectis Innovation Days Episode 4 cellectis.com

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “at this time,” “anticipate,” “believe,”

  3. Slide 3: It Takes More Than One Tool To Make A CAR

    It Takes More Than One Tool To Make A CAR FROM TO The one-stop shop for next generation cell and gene therapy P3

  4. Slide 4: The Cell And Gene Therapy Toolbox

    The Cell And Gene Therapy Toolbox Mastering this element is a critical success factor P4

  5. Slide 5: The Cell And Gene Therapy Toolbox

    The Cell And Gene Therapy Toolbox Mastering this element is a critical success factor P5

  6. Slide 6: The Cell And Gene Therapy Toolbox

    The Cell And Gene Therapy Toolbox Mastering these elements are critical success factors P6

  7. Slide 7: The Cell And Gene Therapy Toolbox

    The Cell And Gene Therapy Toolbox Mastering these elements are a critical success factors P7

  8. Slide 8: Gene Editing Technologies

    Part 1 Gene Editing Technologies P8

  9. Slide 9: Our Gene Editing Story

    Our Gene Editing story 21 years 12 years 10 years 8 years High throughput of expertise in of expertise of expertise of expertise Gene Editing gene editing with TALEN® with MegaTAL with CRISPR platform and compact TALEN® PIONEERS OF GENE EDITING >15’500 unique >1’500’000 on/off TALEN®/DNA sites data

  10. Slide 10: Cellectis Patents Global Overview

    Cellectis Patents Global Overview CELLECTIS PATENT PORTFOLIO (124 patent families) Granted patents (278) Pending patent applications (316) Other Other US EP US EP territories territories Cellectis 60 52 127 56 43 178 Excusive 17 6 16 6 6 27 In-Licensing P10

  11. Slide 11: Cellectis Patents Global Overview

    Cellectis Patents Global Overview Cellectis Compact Gene editing Meganucleases TALEN® MegaTAL CRISPR Total TALEN® applications Portfolio Patent 9 8 2 2 4 18 105 families Delivered 34 37 13 10 16 42 239 patents Pending 1 15 4 2 9 117 277 applications Latest Expiration 2031 2035 2034 2034 2034 2038 20

  12. Slide 12: TALEN For Gene Editing: Best-in-class platform

    TALEN® For Gene Editing Best-in-class gene editing platform P12

  13. Slide 13: The Three Pillars Of Gene Editing For Therapeutic Applications

    The Three Pillars Of Gene Editing For Therapeutic Applications Capacity to induce efficiently a double strand break in the genome Activity Capacity to Capacity to avoid target as close Precision Specificity unintended as possible to genetic the desired modifications site P13

  14. Slide 14: The Three Pillars Of Gene Editing: Precision

    The Three Pillars Of Gene Editing: Precision Activity Capacity to target as close as possible Precision Specificity to the desired site P14

  15. Slide 15: TALEN: Unmatched Targeting Precision

    TALEN®: Unmatched Targeting Precision TALEN® density on Chromosome 2 TALEN® per megabase The whole genome is targetable with a high density of TALEN® • Mean distance between 2 TALEN® sites < 7 bp P15

  16. Slide 16: The Three Pillars Of Gene Editing: Activity

    The Three Pillars Of Gene Editing: Activity Capacity to induce efficiently a double strand break in the genome Activity Precision Specificity P16

  17. Slide 17: TALEN: High Editing Efficiency

    TALEN®: High Editing Efficiency Identification of lead TALEN® Success rate Cleavage activity >90% 100 Frequency of Indels (%) 80 60 40 20 Cleavage activity >70% 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Targeted gene • Proprietary a

  18. Slide 18: The Three Pillars Of Gene Editing: Specificity

    The Three Pillars Of Gene Editing: Specificity Activity Capacity to avoid Precision Specificity unintended genetic modifications P18

  19. Slide 19: TALEN Specificity: State-of-the-art Off-site Validation Process

    TALEN® Specificity: State-of-the-art Off-site Validation Process Robust off-site High throughput off-site identification assessment NGS Indels quantification Off-site Indels (NGS) Cellectis Off-site score Replicate 1 Off-site Replicate 2 • Genome wide identification of potential off-sites • Hundreds

  20. Slide 20: TALEN: Exquisite Specificity

    TALEN®: Exquisite Specificity Cellectis proprietary TALEN® design Rational Design On-site Off-site Protein engineering to reach perfect specificity for therapeutic P20 applications

  21. Slide 21: TALEN Specificity: Protein Engineering To Expand The Recognition Code

    TALEN® Specificity: Protein Engineering To Expand The Recognition Code Direct Protein: DNA contact Extending the TALE Code Targeted nucleotide 1st Amino Acid of RVD A C HD: G T C NG: T NI:A NN: G 2nd Amino Acid of RVD From a 4 RVD code to >200 targeting modules allow P21 exquisite control of targeti

  22. Slide 22: Controlling TALEN Specificity By Expanding The Recognition Code

    Controlling TALEN® Specificity By Expanding The Recognition Code P22

  23. Slide 23: Controlling TALEN Specificity By Expanding The Recognition Code

    Controlling TALEN® Specificity By Expanding The Recognition Code Expanding the “targeting code” Suppress off site + Maintain on-site 1.5 100 Off-site Indels [%] On-site Indels [%] 80 1.0 >100-fold 60 40 0.5 20 0.0 0 de de de de co co co co ed ic ed ic ss s d d as an an la cl C p p ex ex Targeting sp

  24. Slide 24: TALEN Specificity: Design Of An Allele-specific TALEN

    TALEN® Specificity: Design Of An Allele-specific TALEN® Mutation specific WT sequence TALEN® TALEN® Mutation Cells Mutation Cells WT Cells WT Cells 1bp 1bp Cut Cut differenc differenc e e TALEN® can be designed to discriminate to a single base pair P24 resolution

  25. Slide 25: Experimental considerations

    TALEN® For Gene Editing Experimental considerations P25

  26. Slide 26: TALE: A Versatile Gene Editing Platform

    TALE: A Versatile Gene Editing Platform X KI with KO Gene KO Gene Repair Gene replacement Gene insertion X Nuclease KI without KO Base editor KI with controlled expression Gene KO Gene Repair

  27. Slide 27: TALE: A Versatile Scaffold For Efficient Base Editing

    TALE: A Versatile Scaffold For Efficient Base Editing High editing efficiency TALE Base Editors 100 ~90% C•G to T•A [%] 80 60 40 Repeat Variable di-residues 20 N-terminal Deaminase Head (RVD) 0 TALE CTGGAGTTGACTAAA TALE Heterodimeric base editor binding GACCTCAACTGATTT binding High editing precision

  28. Slide 28: A Fully Integrated Gene Editing Platform

    TALEN® For Gene Editing A fully Integrated Gene Editing platform P28

  29. Slide 29: TALEN: Best-in-class Gene Editing Platform

    TALEN®: Best-in-class Gene Editing Platform Genomic sequence Database TALEN® design TALEN® assembly mRNA synthesis >1,500,000 protein- in primary human MINUTES < 1 DAY < 1 Week cells DNA data points in primary human cells < 1 MONTH Activity Specificity Genome wide analysis Epigenetic P29 context

  30. Slide 30: Gene Editing Technologies

    Part 2 Gene Editing Technologies P30

  31. Slide 31: Introduction

    Introduction Key Messages: • The future of cell therapy lies in smart cells that will do what normal cells cannot. • It’s all going to be about genome engineering : programming cells to execute predetermined scenarios once infused in patients • At Cellectis, we are already in the era of genome desig

  32. Slide 32: Genome Engineering Is Transforming Cell Therapies

    Genome Engineering Is Transforming Cell Therapies Smart cells industrial platform ü Genome design t j us Ad ü Programming scenarios t us A dj Strategic capability for § multiple cell types (T-cells, stem cells, etc.) § fast versioning (key to incremental development for complex indications) P32

  33. Slide 33: Robust Delivery Is Key For Yield

    Robust Delivery Is Key For Yield Genome engineering relies on § brief DNA surgery § long-lasting effects, § in billions of primary cells Þ Deliver messenger RNA, DNA, vectors. High and robust yields allow clinical & commercial deployment P33

  34. Slide 34: A Platform Based On Electroporation

    A Platform Based On Electroporation § Delivery with electroporation: versatile (DNA, mRNA, proteins) with any cell type, scalable, robust § High electric fields open pores in the outer cell membrane. § low voltage electric pulses drag macromolecules into the cells through the pores. § It takes a few

  35. Slide 35: Controlling Gene Delivery From End To End

    Controlling Gene Delivery From End To End Cellectis acquired the Cytopulse technologies in 2010 and built upon it its own electroporation capability: - + ü devices ~ ü reagent and buffers ü process and electrical wave forms Þ for each cell and payload types P35

  36. Slide 36: PulseAgile: Wholly Owned Industrial Gene Editing Delivery Platform

    PulseAgile: Wholly Owned Industrial Gene Editing Delivery Platform Mastering and controlling genome engineering from end to end • PulseAgile: electric wave form generator deliver precise, controlled and flexibly adjustable pulses P36

  37. Slide 37: Electroporation Of Billions Of Cells

    Electroporation Of Billions Of Cells Proprietary electroporation chamber designed for billions of cells 1.00 E+0 9 9.00 E+0 8 8.00 E+0 8 (viable edited cells / run) 7.00 E+0 8 6.00 E+0 8 TRAC - + 5.00 E+0 8 Yield 4.00 E+0 8 3.00 E+0 8 2.00 E+0 8 ~ 1.00 E+0 8 B2M/Class I HLA 0.00 E+0 0 1 2 3 Single p

  38. Slide 38: Proprietary Chemically Designed Buffers

    Proprietary Chemically Designed Buffers Making proprietary electroporation buffers for each cell and payload types. Screening vast chemical space along critical buffer properties P38

  39. Slide 39: Optimizing Electroporation For Any Application

    Optimizing Electroporation For Any Application Example for hemopoietic stem cells Optimization 80 Scale up % edit 70 Electric wave form optimization Buffer 60 optimization 0 2 4 6 8 10 Relative Relative yield inyield viable cells P39

  40. Slide 40: Edits With Yield And Accuracy

    Edits With Yield And Accuracy Examples in hemopoietic stem cells (HSC) HSC transfection HSC gene editing MHC Class I 98,2% FITC 78,3% FSC FSC Hundred millions cells scale P40

  41. Slide 41: Scaling to hundred billions of cells: GeneEngine

    Industrialization Scaling to hundred billions of cells : GeneEngine™ P41

  42. Slide 42: GeneEngine For Hundreds Of Billions Of Cells

    GeneEngine™ For Hundreds Of Billions Of Cells Expanding to hundreds of billions of cells GeneEngineTM provides üVersatility : any cell type üScalability üRobustness: closed system üYield P42

  43. Slide 43: Robustness At Industrial Scale

    Robustness At Industrial Scale Examples in T-cell 1.20E+11 1.00E+11 Yield (Cells) 8.00E+1 0 6.00E+10 4.00E+10 2.00E+10 0.0 0E+00 0 20 40 60 80 100 Minutes P43

  44. Slide 44: Era Of Genome Design

    Era Of Genome Design Genome design for industrial deployment Genomic engineering for simple functions TALEN®-enabled First nuclease-based single knock-in gene knockout 2021 2017 2011 1999 P44

  45. Slide 45: A Unique Smart Cell Technological Platform

    A Unique Smart Cell Technological Platform Unique position: short time from genomic design to bed side and rapid versioning ü TALEN® for therapeutics: exquisite precision, activity and specificity ü Fast target to therapeutic TALEN® turnaround ü End to end controlled versatile and scalable vectoriza

  46. Slide 46: Thank You

    THANK YOU Reach us at: investor@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 430 East 29th Street 2500 Sumner Boulevard 75013 Paris – France 10016 New York, NY – USA 27616 Raleigh, NC – USA

Cellectis — Technical Presentation (July 2021) on 6ix